Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
Introduction Multiple myeloma (MM) is an incurable malignant neoplasm that accounts for approximately 1% of all cancers and 10% of haematological malignancies. Bortezomib is one of the most commonly used medications in first-line treatment and subsequent relapses, either as a single agent or in comb...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/6/e061808.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|